Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. In this phase 3 randomized, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Tri, Gerber, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468595/
https://www.ncbi.nlm.nih.gov/pubmed/30875928
http://dx.doi.org/10.3390/cancers11030366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468595/
https://www.ncbi.nlm.nih.gov/pubmed/30875928
http://dx.doi.org/10.3390/cancers11030366

Ejemplares similares